OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Pharmacotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention	47
Pneumocystis jirovecii: a review with a focus on prevention and treatment	45
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis	41
Current pharmacological approaches to the treatment of tendinopathy	37
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction	33
Capsaicin 8% dermal patch in clinical practice: an expert opinion	31
An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection	29
Can NSAIDs and Acetaminophen Effectively Replace Opioid Treatment Options for Acute Pain?	28
Are 5-HT₁ receptor agonists effective anti-migraine drugs?	26
New anti-seizure medication for elderly epilepsy patients - a critical narrative review	25
Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases	24
The pharmacological management of chronic lower back pain	24
An update on direct antiviral agents for the treatment of hepatitis C	24
Advances with glucocorticoids in the treatment of asthma: state of the art	23
Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspective	23
Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options	22
An evaluation of avatrombopag for the treatment of thrombocytopenia	20
Pharmacotherapeutic strategies for castrate-resistant prostate cancer	20
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies	20
AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation	20
Current and new pharmacotherapeutic approaches for glaucoma	20
Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders	19
An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease	19
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile	19
Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art	18

Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance	18
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia	18
How urgent is the need for new antifungals?	18
An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage	17
State-of-the-art pharmacotherapy for diabetic neuropathy	17
The pharmacological management of vertigo in Meniere disease	17
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options	17
Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects	16
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia	16
Ponesimod for the treatment of relapsing multiple sclerosis	16
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis	16
Careful use to minimize adverse events of oral antidiabetic medications in the elderly	16
The role of sulfonylureas in the treatment of type 2 diabetes	15
The evolving atopic dermatitis management landscape	15
Are thiazolidinediones a preferred drug treatment for type 2 diabetes?	15
The role of amikacin in the treatment of nontuberculous mycobacterial disease	15
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout	15
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain	15
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	15
Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems	15
Cenobamate for the treatment of focal epilepsies	15
Managing dyslipidemia in patients with Type 2 diabetes	14
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease	14
Quizartinib for the treatment of acute myeloid leukemia	14
A review of a new voltage-gated Ca²⁺ channel α₂δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain	14
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy	14
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients	14
Novel synthetic treatment options for migraine	14
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.	14
State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma	13
An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective	13
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy	13
Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review	13
Current and emerging pharmacotherapy for recurrent bacterial vaginosis	13
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia	13
Evaluating rimegepant for the treatment of migraine	13
Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer	12
Pharmacological management of secondary spinal cord injury	12
Pharmacological strategies to treat attacks of episodic migraine in adults	12
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG	12
Are drug treatment strategies really effective against alopecia areata?	12
Current and promising pharmacotherapeutic options for candidiasis	12
The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)	12
Management of cardiovascular disease in patients with systemic lupus erythematosus	12
A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020	12
Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia	11
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations	11
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis	11
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	11
Advances with androgen deprivation therapy for prostate cancer	11

An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis	11
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients	11
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	11
Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment	11
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease	10
Evaluating vibegron for the treatment of overactive bladder	10
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review	10
Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics	10
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma	10
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation	10
Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma	10
Evaluating pitolisant as a narcolepsy treatment option	10
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma	10
Advances in pharmacotherapies for hyperuricemia	10
Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients	10
The complement system: a novel therapeutic target for age-related macular degeneration	10
Pharmacological treatment of focal epilepsy in adults: an evidence based approach	10
Bexagliflozin for type 2 diabetes: an overview of the data	10
New perspectives on the definition, diagnosis, and treatment of true arterial hypertension	10
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer	10
Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancer	10
Advances in pharmacotherapy for diabetic foot osteomyelitis	10
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?	9
Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?	9
Evaluating entrectinib as a treatment option for non-small cell lung cancer	9
Current and emerging systemic treatments targeting the neural system for chronic pruritus	9
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China	9
Drug treatment options for acute promyelocytic leukemia	9
Current and emerging drug treatment strategies for peripheral arterial disease	9
Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability	9
Pharmacotherapeutic management of trigeminal neuropathic pain: an update	9
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)	9
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer	9
The management of hematologic malignancies during the COVID-19 pandemic	9
Ensitrelvir as a potential treatment for COVID-19	9
Current and future pharmacotherapy options for drug-resistant epilepsy	9
Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature	9
An update on the available and emerging pharmacotherapy for adults with testosterone deficiency available in the USA	9
An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain	9
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	9
Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes	9
Pharmacotherapy for artemisinin-resistant malaria	9
Pharmacological management of human respiratory syncytial virus infection	9
Current and emerging drug treatment strategies for polycystic ovary syndrome	8
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors	8
Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: an UK national cross-sectional audit	8
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	8
An evaluation of apalutamide for the treatment of prostate cancer	8
Advances in the psychopharmacotherapy of bipolar disorder type I	8
State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma	8
The clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine	8
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	8
Evaluating ivosidenib for the treatment of acute myeloid leukemia	8
Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist	8
Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?	8
How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections?	8
Pharmacological strategies for improving the prognosis of glioblastoma	8
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia	8
Protein kinase inhibitors for the treatment of prostate cancer	8
Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication	8
Does hydroxychloroquine still have any role in the COVID-19 pandemic?	8
Osilodrostat for the treatment of Cushing’s disease	8
An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease	8
Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations	8
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy	8
Advances in the pharmacological management of bacterial peritonitis	8
An update on antidepressant pharmacotherapy in late-life depression	7
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer	7
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease	7
Combinational therapies for the treatment of advanced cervical cancer	7
Current and emerging pharmacotherapy for pediatric allergic rhinitis	7
An evaluation of cabotegravir for HIV treatment and prevention	7
Expert guidance on the management and challenges of long-COVID syndrome: a systematic review	7
Advances in the pharmacological management of non-24-h sleep-wake disorder	7
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors	7
Oral pharmacotherapeutics for the management of peripheral neuropathic pain conditions – a review of clinical trials	7
A review of the pharmacotherapeutic considerations for managing epilepsy in people with autism	7
Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update	7
The potential role of elagolix for treating uterine bleeding associated to uterine myomas	7
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	7

Desvenlafaxine in the treatment of major depression: an updated overview	7
Pharmacotherapeutic considerations in women with multiple sclerosis	7
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis	7
An update on the impact of depression on the treatment of psoriasis	7
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges	7
What are the treatment options for resistant Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria?	7
An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer	7
Relapse prevention in panic disorder with pharmacotherapy: where are we now?	7
Advances in pharmacotherapy for neuroblastoma	7
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	7
Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer	7
Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes	7
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion	7
The pharmacological treatment and management of hyperhidrosis	7
Relugolix for the treatment of uterine fibroids	6
The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma	6
Evaluating filgotinib for the treatment of rheumatoid arthritis	6
Pharmacotherapeutic considerations for late-onset epilepsy	6
How treatable is narcolepsy with current pharmacotherapy and what does the future hold?	6
Alitretinoin for the treatment of severe chronic eczema of the hands	6
Pharmacotherapeutic advances for recurrent urinary tract infections in women	6
What is the impact of pharmacotherapy on psychotherapy for obsessive-compulsive disorder?	6
Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma	6
What place do carbamazepine-related antiepileptic drugs have in the modern day treatment of epilepsy?	6
An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development	6
Advances in pharmacotherapy for acute and recurrent pericarditis	6
Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity	6
An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections	6
Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?	6
Balancing treatments for patients with systemic hypertension and glaucoma	6
Advances in pharmacotherapy for acute kidney injury	6
Pharmacological management of adult patients with acute respiratory distress syndrome	6
Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion	6
Pharmacotherapy for trichotillomania in adults	6
An update on pharmacotherapeutic strategies for obesity	6
The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation	6
Current challenges in the pharmacological management of genitourinary syndrome of menopause	6
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV	6
Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19	6
Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity	6
Pharmaceutical management of sexual dysfunction in men on antidepressant therapy	5
Is pharmacotherapy useful for treating personality disorders?	5
Advances in pharmacotherapy for head and neck cancer	5
New and emerging pharmacological treatment options for acromegaly	5
Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia	5
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care	5
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update	5
The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications	5
Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?	5
Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan	5
Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	5
Vortioxetine in management of major depressive disorder – a favorable alternative for elderly patients?	5
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors	5
Advances in pharmacotherapeutics for hepatocellular carcinoma	5
Rethinking the use of hypnotics for treatment of insomnia in the elderly	5
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	5
Perspectives on the use of non-biological pharmacotherapy for adult-onset Still’s disease	5
Drug treatment strategies for secondary diabetes in patients with acromegaly	5
Treatment strategies for isolated systolic hypertension in elderly patients	5
Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction	5
Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime	5
What’s new on the front-line of gout pharmacotherapy?	5
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)	5
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy	5
Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease	5
Treatment of type 2 diabetes in children: what are the specific considerations?	5
Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far	5
Current and promising therapeutic options for Dravet syndrome	5
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women	5
Treatment of severe COVID-19: an evolving paradigm	5
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma	5
Azole resistance in Aspergillus species: promising therapeutic options	5
What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?	5
Tafenoquine for the treatment of Plasmodium vivax malaria	5
An evaluation of selexipag for the treatment of pulmonary hypertension	5
How do we address treating the negative symptoms of schizophrenia pharmacologically?	5
The treatment of advanced lung adenocarcinoma with activating EGFR mutations	5
Evaluating upadacitinib for the treatment of psoriatic arthritis	5
Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) infection: what are the challenges?	5
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors	5
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study	5
An update on current pharmacotherapy for vulvar cancer	5
Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients	5
Current therapeutic options for glioblastoma and future perspectives	5
The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder	5
Key considerations in the pharmacological management of treatment-resistant depression	5
Pharmacotherapeutic management of asthma in the elderly patient	5
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	5
Vibegron for the treatment of overactive bladder: a comprehensive update	5
Guidance for the pharmacological management of COVID-19 in the emergency setting	5
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus	5
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date	5
Pharmacotherapeutic management of atopic keratoconjunctivitis	5